Industry News

The announcement comes days before the FDA's regulatory decision on the CRISPR-based gene-therapy exa-cel.

Sanofi has signed a multi-year $140 million research deal with the Paris-based startup

The collab will give AstraZeneca access to Absci's generative AI platform with the goal of accelerating the discovery of a potential new cancer treatment

The merger positions Roche with both injectable and oral obesity drug candidates.

News of the partnership broke a day after its announcement of a $500 million deal with Boehringer Ingelheim

The biotech plans to harness AWS's global infrastructure and services for its new assembly and packaging site in Ohio

Protein-protein interactions were also a key piece of Lilly’s $2.4 billion Dice buyout this year

In one of the largest biopharma M&A deals this year, AbbVie grabs the only approved ovarian cancer ADC

In a deal that could exceed $500 million, Boehringer will use Phenomic's scTx single-cell transcriptomics platform to develop first-in-class medicines

BARDA has awarded a contract option to Emergent for the acquisition of its newly licensed anthrax vaccine

The expanded partnership will focus on antibody oligonucleotide conjugates

The drugmaker will use a pre-trained AI model to make the vision of in silico biologic drug discovery a reality.

An FDA AdComm will meet to discuss the companies’ proposed use of Abecma in earlier lines of treatment for multiple myeloma

The drugmaker has not received any reports of adverse events related to this issue

The Swedish biotech has discontinued a trial of its lead asset following the advice of an independent data monitoring committee

After exhaustive efforts to explore funding alternatives, the biotech will be closing its doors

Aiming to fast-track drug discovery, the two will link experimental data to algorithms with AI precision.

The partners will work to bring the potential first-in-class CDK2-specific drug to the clinic

The company’s financial woes deepen as its trial for diabetic macular edema yields disappointing results.

The drugmaker is recalling one lot of Vitrakvi following the discovery of microbial contamination

In the deal, Astellas will pick up a phase 1 injectable version of J&J's Zytiga

The site will support the surging demand for the drugmaker's diabetes and obesity portfolio

The tyrosine kinase inhibitor was the driving force behind BMS' $4.1 billion acquisition of Turning Point Therapeutics

The UK has approved exa-cel for the treatment of sickle cell disease and transfusion-dependent beta thalassemia

The Gilead company is extending its partnership into lymphomas and multiple myeloma

The California-based immunotherapy biotech has announced its third reorg in recent history

The Australian biopharma has proposed a $33.1 million acquisition of the bone cancer specialist

A phase 3 trial to evaluate concurrent Imfinzi administration with chemoradiotherapy failed to meet its endpoint

The drugmaker has inaugurated a penicillin production facility in Kundl, Austria and a new biosimilar development center in Holzkirchen, Germany

Switzerland-based Basilea Pharmaceutica will acquire the rights to fosmanogepix, a phase 3-ready broad-spectrum antifungal candidate